• Publications
  • Influence
Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy.
BACKGROUND Chronic kidney disease (CKD) is a common co-morbidity of patients with atherosclerotic vascular disease, and may influence the response to antiplatelet therapy. We, therefore, sought toExpand
  • 72
  • 4
Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
A high on-treatment residual ADP-inducible platelet reactivity in light transmission aggregometry (LTA) has been associated with an increased risk of adverse outcomes after percutaneous coronaryExpand
  • 99
  • 2
Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb.
BACKGROUND Soluble p-selectin (sP-selectin), D-dimer, and C-reactive protein (CRP) are elevated in deep vein thrombosis (DVT), and may play a role as risk predictors of recurrent venousExpand
  • 38
  • 2
The Influence of Proton Pump Inhibitors on the Antiplatelet Potency of Clopidogrel Evaluated by 5 Different Platelet Function Tests
Proton pump inhibitors (PPIs) are metabolized by the cytochrome P450 enzyme system to a variable degree and may therefore interact with the metabolism of clopidogrel to its active form. TheExpand
  • 30
  • 2
Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation
Urinary 11-dehydro thromboxane B2 (d-TXB2) concentrations in the highest quartile have been associated with an increased risk of adverse outcomes in patients at high risk for atherothrombotic events.Expand
  • 24
  • 2
A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity.
BACKGROUND Patients with high on-treatment residual adenosine diphosphate-inducible platelet reactivity (HRPR) despite clopidogrel therapy are at an increased risk for adverse events after coronaryExpand
  • 14
  • 2
Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy.
BACKGROUND High on-treatment residual platelet reactivity is associated with an increased risk of adverse events after coronary stenting. Recent data suggest that cigarette smoking might enhanceExpand
  • 56
  • 1
Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests.
BACKGROUND The antiplatelet effect of clopidogrel is subject to considerable inter-individual variations. In vitro high on-treatment residual platelet reactivity (HRPR) has been linked to cytochromeExpand
  • 26
  • 1
Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease
Blood coagulation is essential for physiological hemostasis but simultaneously contributes to thrombotic disease. However, molecular and cellular events controlling initiation and propagation ofExpand
  • 22
  • 1
The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity.
BACKGROUND Circulating monocyte-platelet aggregates (MPA) are a sensitive marker of in vivo platelet activation and patients with atherosclerotic vascular disease exhibit higher levels of MPA.Expand
  • 16
  • 1